SCHEMBL6496308

SCHEMBL6496308

O=C(Nc1ccccn1)c1c[nH]c2c1C(=O)C1CN(Cc3ccccc3)CC1CC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.46
DRD4 P21917 2/20 0.46
DRD3 P35462 2/20 0.46
SGMS2 Q8NHU3 1/20 0.39
PDCD1 Q15116 3/20 0.38
CD274 Q9NZQ7 3/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SIGMAR1 Q99720 1/20 0.37
GRIN2B Q13224 1/20 0.37
FAAH O00519 1/20 0.37
NR3C1 P04150 1/20 0.36
MET P08581 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501831 0.85 NPC1 (0.40) KDM4EMEN1KMT2AL3MBTL1CHRNB2
SCHEMBL6495856 0.80 MEN1 (0.40) KDM4EMEN1KMT2AL3MBTL1CHRNB2
SCHEMBL6309546 0.73 DRD2 (0.43) DRD2DRD4DRD3SGMS2KDM4E
SCHEMBL6502758 0.72 NPC1 (0.56) KDM4EMEN1KMT2AL3MBTL1CHRNB2
SCHEMBL7385161 0.70 BUB1 (0.49) KDM4EMEN1KMT2AL3MBTL1CHRNB2
SCHEMBL6493715 0.69 NPC1 (0.43) KDM4EMEN1KMT2AL3MBTL1CHRNB2
SCHEMBL6497908 0.69 NPC1 (0.41) KDM4EMEN1KMT2AL3MBTL1CHRNB2
SCHEMBL6494383 0.67 RXFP1 (0.40) KDM4EMEN1KMT2AL3MBTL1CHRNB2
SCHEMBL6309523 0.67 MEN1 (0.43) KDM4EMEN1KMT2AL3MBTL1CHRNB2
SCHEMBL6309724 0.65 MEN1 (0.44) KDM4EMEN1KMT2AL3MBTL1CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861529-B2 Cycloalkylpyrrole-3-carboxylic acid amide derivatives and heterocycloalkylpyrrole-3-carboxylic acid amide derivatives that bind with high affinity to the benzodiazepine site of GABA-A (gamma-aminobutyric acid) receptors PFIZER INC (US) 2005-03-01 US claimed
US-20030069416-A1 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives PFIZER INC. 2003-04-10 US claimed
US-6861529-B2 Cycloalkylpyrrole-3-carboxylic acid amide derivatives and heterocycloalkylpyrrole-3-carboxylic acid amide derivatives that bind with high affinity to the benzodiazepine site of GABA-A (gamma-aminobutyric acid) receptors PFIZER INC (US) 2005-03-01 US disclosed
EP-1404316-A1 CYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND HETEROCYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AS GABA-A RECEPTOR LIGANDS Pfizer Products Inc. (US) 2004-04-07 EP disclosed
US-20030069416-A1 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives PFIZER INC. 2003-04-10 US disclosed
WO-2003004018-A1 CYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AND HETEROCYCLOALKYLPYRROLE-3-CARBOXYLIC ACID DERIVATIVES AS GABA-A RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069416-A1 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives GABARAP, GABRA3, GABRA2 DRD2 414/4885DRD4 686/4885DRD3 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.